
Biopharma QC
Guides, reagent insights and news from BIORI on biopharma QC.
Biopharma QC: explore the sub-topics.

Host Cell Proteins: From Total HCP Limits to Risk-Based Control
Host cell proteins carry different risks: why total HCP ELISA limits miss high-risk HCPs, the BPDG risk categories, and how to build risk-based HCP control.
Read the article
Spiroplasma in Insect-Cell Bioprocesses: Risk and qPCR Detection
Spiroplasma testing for Sf9, High Five and S2 insect cell processes: how it differs from mycoplasma, culture vs qPCR, and what ChP, USP and Ph. Eur. expect.

Mycoplasma qPCR Testing for Biologics
Learn how to evaluate mycoplasma qPCR testing for biologics, including LoD, target coverage, matrix suitability, controls, and Spiroplasma detection.

Residual Host Cell DNA Testing by qPCR: Choosing CHO or E. coli Assays
Learn how residual host cell DNA testing by qPCR differs for CHO and E. coli workflows, and how to assess LoD, LoQ, linearity, recovery, and controls.

Residual DNA Testing for Gene Therapy Manufacturing: A Practical QC Guide
A practical guide to residual DNA testing in gene therapy and biomanufacturing QC, covering method selection, sample prep, HCP/HCD risk, and supplier considerations.

Meet BIORI at ASGCT 2026 in Boston, MA | Booth 1511
Meet BIORI at ASGCT 2026, Booth No. 1511, to discuss HCD/HCP testing solutions, universal nuclease, and customized kit development services for CGT manufacturing and QC.
Need help choosing a reagent or format?
Tell us which enzyme or format you are evaluating. Our team replies within one business day.

